Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
← catalyst calendarSponsored by Recursion Pharmaceuticals Inc. (industry) · RXRX — their whole pipeline →.
Phase
Phase 2/3
Status
Terminated
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
25actual
Sites
15
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Study was terminated due to sponsor decision. This decision was not related to safety concerns with REC-2282.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-20 | actual | When the study began enrolling |
| Primary completion | 2025-08-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-18 | actual | The whole study's end, after follow-up |
| First posted | 2021-11-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Neurofibromatosis Type 2
Interventions
- Drug: REC-2282 — also filed as AR-42, OSU-HDAC42, NSC-D736012
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFCohort A: Number of Participants with Progression-free survival (PFS) at 6 Months
measured 6 months
Cohort B: Number of Participants with PFS up to 3 years
measured Up to 3 years
Permalink · RXRX's whole pipeline · Catalyst calendar · Every registered study · What changed